Please assess the completion status of the following clinical trial:

Trial Title: Cranoc Lipid Study in Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients (18 - 65, inclusive)~* cadaver and living kidney transplantation (1. Ntx, 2. Ntx)~* LDL-cholesterol ≤ 130mg/dl (-3 Mo until start of Tx)~* Patients with a history of Myocard infarct: LDL-Cholesterol ≤ 110mg/dl~* Immunsuppression: Tacrolimus in combination with steroids or Mycophenolat Mofetil~* patients indulgence~Exclusion Criteria:~* statin before the study~  * LDL-Cholesterol \>130mg/dl before transplantation~ * Instabil Angina, Myocard infarct \<6 months before transplantation~ * symptomatic Hypothyreosis~ * child bearing, lactating~ * elavated liver encymes (\> 2x elavated: AST, ALT, bilirubine, PCK)~ * Fibrates are not allowed~ * multiorgantransplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (therapy with fluvastatin 80mg retard) (Type: NO_INTERVENTION): kidney transplants receive in addition fluvastatin 80mg retard for 3 years
- B (Type: PLACEBO_COMPARATOR): no therapy with fluvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).